Article

Lifecycle management of orphan drugs approved in Japan

2022-05-23

Abstract excerpt

<title>Abstract</title> <p><bold>Background:</bold> The development of orphan drugs (ODs) is challenging from both development and business perspectives because of their small patient populations. To overcome such business challenges, lifecycle management (LCM), which maximizes profits by increasing sales and extending product lifetimes, is important to overcome the business challenges arising from their small pa...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 4f942c9a-c538-5067-8807-0bab687cb4d9
DOI: 10.21203/rs.3.rs-1451942/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Lifecycle management of orphan drugs approved in JapanDOI 10.21203/rs.3.rs-1451942/v1Read

U.S. Food and Drug Administration utilization of postmarketing requirements and postmarketing commitments, 2009-2018Semantic proximity Read

Analysis of Patient Access to Orphan Drugs in TurkeySemantic proximity Read

A Decade of Innovation: Medicinal Products with New Active Substances Centrally Authorized Within EU Between 2011 and 2020Semantic proximity Read

Pharmaceutical Drug Lifecycle: A Comprehensive Scientific Review of Research and Development Phases, Attrition Rates, and Global DisparitiesSemantic proximity Read

Implementation status of pharmacological studies in the development of orphan drugsSemantic proximity Read

Access to Essential and Innovative Anti-cancer Medicines: A Longitudinal Study in Nanjing, ChinaSemantic proximity Read

Trend Analysis of Regulatory Approval Pathways and Major Shifts in Pivotal Clinical Trial Designs for Antineoplastic Drugs Approved by the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) From 2004 to 2019.Semantic proximity Read

Calendar Period Estimation of Probabilities of Transition in Drug DevelopmentSemantic proximity Read

Academic challenges on ATMPs’ development: a regulatory perspectiveSemantic proximity Read

Time to Patients’ Access to New Medicines in Greece: Evaluation of Health Technology Assessment (HTA) Process from July 2018 until January 2021.Semantic proximity Read

Use of over-the-counter-like drugs among adults with indicated chronic diseases: A nationwide descriptive study in JapanSemantic proximity Read

Current Situation of Clinical Trials of Drugs for Children's Indications in ChinaSemantic proximity Read